VIP Peptide Stability: Mapping Its Degradation Routes for QC
Vasoactive intestinal peptide, usually shortened to VIP, is a 28-residue amidated neuropeptide studied at the VPAC1 and VPAC2 receptors in in-vitro work. From a quality-control point of view, the VIP peptide is notable for something else: its sequence contains almost every residue type prone to chemical change. Aged or poorly stored material rarely shows one tidy impurity. It shows a cluster of small peaks with several different mass shifts. This article maps where each change happens, how to recognise it in data, and how a lab holding VIP stock over months can keep its lots under control.
The sequence and where the weak points sit
The sequence is:
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Its average mass is about 3326 Da, with a monoisotopic value near 3323.8 Da. Reading along the chain, the positions worth marking are:
| Position(s) | Residue | Change | Mass shift | Typical chromatographic sign |
|---|---|---|---|---|
| 17 | Methionine | Oxidation to sulfoxide | +16 Da | New peak eluting before the parent |
| 9, 24, 28 | Asparagine | Deamidation to Asp or isoAsp | +0.98 Da each | Small peaks close to the parent |
| 3, 8 | Aspartate | Succinimide formation, then isoAsp | −18 Da, then 0 | Transient intermediate; isoAsp shows only by retention |
| 10, 22 | Tyrosine | Oxidative modification | Various | Less common; altered 280 nm response |
| C-terminus | Amide | Free acid instead of amide | +0.98 Da | Close to the parent |
VIP peptide degradation, route by route
Methionine oxidation
The single methionine at position 17 reacts with dissolved oxygen, peroxides in solvents and light-generated radicals. The sulfoxide is more polar and elutes earlier on reversed-phase HPLC. It is usually the easiest degradation product to spot, because +16 Da is unambiguous.
Asparagine deamidation
Asparagine side chains can lose ammonia through a cyclic succinimide intermediate, ending as aspartate or isoaspartate. The rate depends heavily on the next residue. Asn24 is followed by serine, one of the neighbours known to speed the reaction, and Asn28 sits at the amidated C-terminus. Asn9, followed by tyrosine, tends to be slower.
Aspartate isomerisation
Aspartate can form the same five-membered succinimide ring, briefly appearing 18 Da light, before reopening. When it reopens as isoaspartate, the mass returns to exactly that of the parent. Only chromatography reveals it, which is one reason a mass-only identity check does not describe the stability of a lot.
A mass-spectrometry trap: two changes, one shift
Deamidation of any asparagine replaces an NH2 group with an OH, adding about 0.98 Da. A C-terminus left as a free acid instead of an amide makes exactly the same substitution and exactly the same shift. On a 3.3 kDa molecule, both appear as a peptide roughly one dalton heavy.
They have very different origins. The free acid is a synthesis issue present from the start; deamidation is a storage issue that grows over time. Telling them apart needs one of:
- Tandem MS, which places the extra mass at a specific residue or at the C-terminus.
- Chromatographic comparison with a reference, since the species usually elute at different times.
- Tracking over time. If the +0.98 species is constant across the life of a lot, it is probably a synthesis variant; if it grows, it is deamidation.
Resolving a one-dalton difference at this mass also needs a reasonably high-resolution instrument, because the isotope clusters overlap.
Using the tyrosines as a second check
With tyrosines at positions 10 and 22, VIP absorbs usefully at 280 nm as well as at 214 nm. That lets a lab record both wavelengths and compare the ratio of 280 to 214 nm area for each peak. Impurities that keep both tyrosines should show a ratio similar to the parent. A peak with a clearly lower ratio has probably lost an aromatic residue, for example a truncation that removed the C-terminal region containing Tyr22. For a sequence with this many possible variants, that extra dimension of evidence is valuable.
Charge, structure and peak shape
VIP carries a clear net positive charge at acidic working pH, from two arginines, three lysines, the N-terminal histidine and the free amine, against only two aspartates. That means tailing on silica columns unless the mobile phase contains an effective ion-pairing acid such as TFA.
The peptide is largely unstructured in water but forms helix in organic solvent or membrane-like environments. Sample diluent and the organic content at injection can therefore influence peak shape. Two labs that dissolve their analytical samples differently may see slightly different chromatograms from the same lot.
Controlling VIP stock over a long programme
Because several routes run in parallel, VIP stock ages as a whole profile rather than as one impurity. For labs that hold a large supply:
- Record the full impurity profile at receipt, not just the headline purity, so later results have a baseline.
- Store lyophilised, cold, dry and dark. Oxidation and deamidation are both much slower in the dry solid.
- Aliquot on arrival into single-use portions to limit repeated exposure to air and moisture.
- Keep analytical solutions short-lived, and run them on a chilled autosampler.
- Re-test older lots and compare against the baseline. Look for growth of the +16 and +0.98 families in particular.
Related family members
VIP belongs to the secretin and glucagon superfamily, alongside PACAP. PACAP-27 and PACAP-38 share N-terminal resemblance with VIP and act at the same VPAC receptors, plus the PAC1 receptor, in the in-vitro literature. They differ in sequence, length and mass, so a partial N-terminal sequence is not enough to tell them apart. The full sequence and an intact mass are the identity check.
Bulk Peptides does not list VIP at present. Our catalogue peptides are HPLC purity tested by an outside lab, certificates are posted for several of them on the certificates of analysis page, and cap and crimp colours match each vial to its paperwork.
VIP and related peptides are covered here as laboratory research materials only. Nothing in this article concerns, or supports, use in humans or animals.
